This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Keytruda
  • /
  • Study of pomalidomide and low dose dexamethasone w...
Clinical trial

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

Read time: 2 mins
Last updated:19th Oct 2015
Identifier: NCT02576977

The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment.

Study Type: Interventional

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment

Official Title: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)

Arms:
-
Experimental: pembrolizumab+pomalidomide+dexamethasone
- Active Comparator: pomalidomide+dexamethasone

Category Value
Date last updated at source 2017-06-16
Study type(s) Randomised clinical trial
Expected enrolment 300
Study start date 2015-10-19
Estimated primary completion date 2019-10-31

View full details